Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) Short Interest Down 12.0% in July

Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) was the target of a significant decrease in short interest in July. As of July 15th, there was short interest totalling 18,400 shares, a decrease of 12.0% from the June 15th total of 20,900 shares. Based on an average daily trading volume, of 224,400 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.3% of the shares of the stock are short sold.

Separately, Zacks Investment Research lowered shares of Hancock Jaffe Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, June 26th.

An institutional investor recently bought a new position in Hancock Jaffe Laboratories stock. Jane Street Group LLC bought a new position in shares of Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 31,692 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned approximately 0.27% of Hancock Jaffe Laboratories as of its most recent SEC filing. Institutional investors own 1.10% of the company’s stock.

Shares of Hancock Jaffe Laboratories stock traded up $0.01 during trading hours on Tuesday, reaching $1.09. 126,600 shares of the company’s stock were exchanged, compared to its average volume of 182,312. Hancock Jaffe Laboratories has a 1 year low of $0.87 and a 1 year high of $3.45. The stock has a market capitalization of $15.02 million and a P/E ratio of -0.57. The firm has a fifty day moving average price of $1.04. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.60 and a quick ratio of 1.60.

Hancock Jaffe Laboratories (NASDAQ:HJLI) last released its earnings results on Thursday, May 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.14. Hancock Jaffe Laboratories had a negative net margin of 5,161.19% and a negative return on equity of 302.90%. The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.03 million.

Hancock Jaffe Laboratories Company Profile

Hancock Jaffe Laboratories, Inc, a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease.

Further Reading: Does a trade war provide a risk to the global economy?

Receive News & Ratings for Hancock Jaffe Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Jaffe Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.